The present and future of digital health, digital medicine, and digital therapeutics for allergic diseases.

IF 4.6 2区医学 Q2 ALLERGY

Clinical and Translational Allergy Pub Date : 2025-01-01 DOI:10.1002/clt2.70020

He Zhang, Yang Cao, Haibo Jiang, Qilin Zhou, Qintai Yang, Lei Cheng

{"title":"The present and future of digital health, digital medicine, and digital therapeutics for allergic diseases.","authors":"He Zhang, Yang Cao, Haibo Jiang, Qilin Zhou, Qintai Yang, Lei Cheng","doi":"10.1002/clt2.70020","DOIUrl":null,"url":null,"abstract":"Background: Digital health, digital medicine, and digital therapeutics integrate advanced computer technologies into healthcare, aiming to improve efficiency and patient outcomes. These technologies offer innovative solutions for the management of allergic diseases, which affect a significant proportion of the global population and are increasing in prevalence. BODY: This review examines the current progress and future potential of digital health in allergic disease management. It highlights key advancements, including telehealth, mobile health (mHealth), artificial intelligence, clinical decision support systems (CDSS), and digital biomarkers, with a focus on their relevance to allergic disease management. The role of digital tools in improving treatment adherence, enabling remote care, and integrating environmental and patient data into personalized care models is discussed. Challenges such as data privacy, interoperability, and equitable access are addressed, alongside potential strategies to overcome these barriers.Conclusion: Digital therapy will play an important role in allergic diseases, and the further development of digital therapies will effectively promote the development of clinical research, digital biomarkers, hypoallergenic environments and digital twins. More research is needed to support the progress of digital therapy for allergic diseases.","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 1","pages":"e70020"},"PeriodicalIF":4.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/clt2.70020","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Digital health, digital medicine, and digital therapeutics integrate advanced computer technologies into healthcare, aiming to improve efficiency and patient outcomes. These technologies offer innovative solutions for the management of allergic diseases, which affect a significant proportion of the global population and are increasing in prevalence. BODY: This review examines the current progress and future potential of digital health in allergic disease management. It highlights key advancements, including telehealth, mobile health (mHealth), artificial intelligence, clinical decision support systems (CDSS), and digital biomarkers, with a focus on their relevance to allergic disease management. The role of digital tools in improving treatment adherence, enabling remote care, and integrating environmental and patient data into personalized care models is discussed. Challenges such as data privacy, interoperability, and equitable access are addressed, alongside potential strategies to overcome these barriers.

Conclusion: Digital therapy will play an important role in allergic diseases, and the further development of digital therapies will effectively promote the development of clinical research, digital biomarkers, hypoallergenic environments and digital twins. More research is needed to support the progress of digital therapy for allergic diseases.

查看原文本刊更多论文

数字健康、数字医学和过敏性疾病的数字治疗的现在和未来。

背景：数字健康、数字医学和数字治疗将先进的计算机技术集成到医疗保健中，旨在提高效率和患者的治疗效果。这些技术为过敏性疾病的管理提供了创新的解决方案，这些疾病影响着全球很大一部分人口，并且患病率正在上升。本文综述了数字健康在变态反应性疾病管理中的当前进展和未来潜力。它强调了关键的进展，包括远程医疗、移动医疗（mHealth）、人工智能、临床决策支持系统（CDSS）和数字生物标志物，重点是它们与过敏性疾病管理的相关性。讨论了数字工具在提高治疗依从性、实现远程护理以及将环境和患者数据集成到个性化护理模型中的作用。解决了数据隐私、互操作性和公平访问等挑战，以及克服这些障碍的潜在战略。结论：数字治疗将在过敏性疾病中发挥重要作用，数字治疗的进一步发展将有效促进临床研究、数字生物标志物、低过敏性环境和数字双胞胎的发展。需要更多的研究来支持过敏性疾病的数字治疗的进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Translational Allergy Immunology and Microbiology-Immunology

CiteScore

7.50

自引率

4.50%

发文量

117

审稿时长

12 weeks

期刊介绍： Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience. Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.